Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

In This Article:

Purple Biotech Ltd.
Purple Biotech Ltd.

CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants

Lead tribody IM1240 data demonstrated that cytokine release is 5T4-dependent and suppressed by the conditionally activated capping technology, suggesting preferred safety profile

Demonstration of additional tribodies suggests CAPTN-3 plug and play platform capability

REHOVOT, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organization for Research and Treatment of Cancer, National Cancer Institute, American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics (the “Triple Meeting”) on October 25, 2024 in Barcelona, Spain.

“CAPTN-3 is a novel technology platform allowing Purple Biotech to develop a variety of new tri-specific antibodies to address different targets on tumors and different mechanisms to treat cancer patients. Our Investigational New Drug (IND) enabling work is aimed to reach first in human clinical studies with our lead candidate IM1240 potentially by 2026,” said Gil Efron, Purple Biotech CEO. “Development of this differentiated platform allows us to potentially offer partners and patients additional antibodies to treat different cancer types.”

CAPTN-3 is a novel platform technology of conditionally activated tri-specific antibodies engaging both T cells and NK cells to target cancers expressing Tumor Associated Antigen (TAA) (αCD3xαTAAxαNKG2A) to induce a strong and selective immune response against the tumor. The addition of the NK engager aims to enhances the tumor-killing activity, providing a key differentiation for more sustained and potent anti-tumor effects. The anti-NKG2A arm also acts as a checkpoint inhibitor enabling simultaneous NK and T-cell activation. This scaffold is designed to be activated only at the tumor microenvironment (TME) to improve the safety profile and extend the therapeutic index. The capped-αCD3 is cleaved by multiple TME-specific proteases, increasing the likelihood of activation by various tumor types. To further extend the capped tribody half-life, human serum albumin is included. CAPTN-3 leverages a plug and play scaffold system providing a flexible design to easily swap and integrate various antibodies to target a wide range of diseases.